Skip Navigation LinksHome > June 2008 - Volume 30 - Issue 6 > Progressive Declines in Neurocognitive Function Among Surviv...
Text sizing:
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e318168e750
Original Articles

Progressive Declines in Neurocognitive Function Among Survivors of Hematopoietic Stem Cell Transplantation for Pediatric Hematologic Malignancies

Shah, Ami J. MD* † ‡; Epport, Karen PhD§; Azen, Colleen PhD§; Killen, Renna RN*; Wilson, Kathy RN*; De Clerck, Dominique RN*; Crooks, Gay MD* † ‡; Kapoor, Neena MD* † ‡; Kohn, Donald B. MD* † ‡; Parkman, Robertson MD* † ‡; Weinberg, Kenneth I. MD

Collapse Box


Neurocognitive function of pediatric patients is of great concern after hematopoietic stem cell transplantation (HSCT). We evaluated the neurocognitive function of pediatric patients pre-HSCT, 1, 3, and 5 years post-HSCT. All patients had a hematologic malignancy and received therapy to their central nervous system. Healthy siblings were tested as a comparison group. Pediatric patients with a hematologic malignancy did not have a significant decrease in their cognitive function before HSCT compared with their siblings except in areas of academic achievement. Our study population had significant declines in visual motor skills and memory test scores within the first year post-HSCT. By 3 years post-HSCT, there was an improvement in the visual motor development scores and memory scores, but there were new deficits in verbal skills. By 5 years post-HSCT, there were progressive declines in verbal skills (P=0.005), performance skills (0.04), and new deficits seen in long-term verbal memory scores (0.04). On the basis of the raw scores, most of these tests showed that patients had an inability to acquire new skills at a rate comparable to their age-matched healthy peers. However, long-term memory scores showed definite declines. The greatest decline in neurocognitive function occurred in those patients who received cranial irradiation either as part of their initial therapy or as part of their HSCT conditioning. Pediatric patients who received HSCT for hematologic malignancies have neurocognitive deficiencies that are both acute and chronic. Although some patients have acute deficits that appear and improve over time, other patients have progressive declines in neurocognitive function that are chronic.

© 2008 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.